Search research articles
Contact Us
Filters
Showing results (161-170 of 189) with videos related to
Page
of 19
Sort By:
BMJ Open Respiratory Research
|
August 18, 2018
Providing safe and effective pleural medicine services in the UK: an aspirational statement from UK pleural physicians
Matthew Evison, Kevin G Blyth, Rahul Bhatnagar, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 7, 2024
Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control
Alexander J Sundermann, Praveen Kumar, Marissa P Griffith, et al.
Journal of Neurology
|
April 12, 2017
The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research
Libby Wood, Isabell Cordts, Antonio Atalaia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 30, 2025
Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact
Alexander J Sundermann, Praveen Kumar, Marissa P Griffith, et al.
The European Respiratory Journal
|
December 18, 2020
Ambulatory management of secondary spontaneous pneumothorax: a randomised controlled trial
Steven P Walker, Emma Keenan, Oliver Bintcliffe, et al.
NPJ Digital Medicine
|
April 10, 2025
Longitudinal voice monitoring in a decentralized Bring Your Own Device trial for respiratory illness detection
Mar Santamaria, Yiorgos Christakis, Charmaine Demanuele, et al.
Therapeutic Advances in Rare Disease
|
March 2, 2026
Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease
Robert J Hopkin, Barry J Byrne, Mazen M Dimachkie, et al.
Journal of Neurology
|
February 17, 2025
Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
Journal of Neurology
|
December 6, 2023
Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
Annals of the Rheumatic Diseases
|
February 26, 2015
Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases
Megan K Herbert, Judith Stammen-Vogelzangs, Marcel M Verbeek, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 189) with videos related to
Sort By:
Page
of 19
BMJ Open Respiratory Research
|
August 18, 2018
Providing safe and effective pleural medicine services in the UK: an aspirational statement from UK pleural physicians
Matthew Evison, Kevin G Blyth, Rahul Bhatnagar, et al.
Medrxiv : the Preprint Server for Health Sciences
|
October 7, 2024
Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control
Alexander J Sundermann, Praveen Kumar, Marissa P Griffith, et al.
Journal of Neurology
|
April 12, 2017
The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research
Libby Wood, Isabell Cordts, Antonio Atalaia, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 30, 2025
Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact
Alexander J Sundermann, Praveen Kumar, Marissa P Griffith, et al.
The European Respiratory Journal
|
December 18, 2020
Ambulatory management of secondary spontaneous pneumothorax: a randomised controlled trial
Steven P Walker, Emma Keenan, Oliver Bintcliffe, et al.
NPJ Digital Medicine
|
April 10, 2025
Longitudinal voice monitoring in a decentralized Bring Your Own Device trial for respiratory illness detection
Mar Santamaria, Yiorgos Christakis, Charmaine Demanuele, et al.
Therapeutic Advances in Rare Disease
|
March 2, 2026
Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease
Robert J Hopkin, Barry J Byrne, Mazen M Dimachkie, et al.
Journal of Neurology
|
February 17, 2025
Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
Journal of Neurology
|
December 6, 2023
Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02)
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, et al.
Annals of the Rheumatic Diseases
|
February 26, 2015
Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases
Megan K Herbert, Judith Stammen-Vogelzangs, Marcel M Verbeek, et al.
Page
of 19